# The Role and Mechanism of Gut Microbiota and Metabolites in Vascular Calcification

## TL;DR

This review explores how gut microbes and their metabolites may influence vascular calcification, a process linked to heart disease.

## Contribution

The paper systematically reviews molecular mechanisms and therapeutic strategies linking gut microbiota to vascular calcification.

## Key findings

- Gut microbiota metabolites like SCFAs, TMAO, and LPS are implicated in vascular calcification processes.
- Dysbiosis in gut microbiota may contribute to vascular pathology through the gut–vascular axis.
- Potential therapies include probiotics, prebiotics, and dietary interventions to manage vascular calcification.

## Abstract

Vascular calcification (VC) is a pathological process involving the deposition of mineral salts within the vascular wall, representing a significant risk factor for the development and progression of cardiovascular disease. The gut microbiota refers to the diverse microbial ecosystem inhabiting the gastrointestinal tract, including bacteria, fungi, viruses, and other microorganisms. This community exhibits considerable variability in both population density and taxonomic composition, with current estimates indicating approximately 1013–1014 microorganisms residing in the human gut. Recent studies suggest that metabolites produced by the gut microbiota may influence the pathogenesis of VC through the gut–vascular axis. This review consolidates current findings on the molecular mechanisms driving VC and examines the potential contribution of gut microbiota dysbiosis to vascular pathology. Particular attention is given to the functional roles of microbial metabolites such as short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), lipopolysaccharide (LPS), uremic toxins, secondary bile acids, and vitamin K in modulating calcific processes. In addition, current limitations in the existing literature are outlined, and potential therapeutic approaches, including probiotic use, prebiotic interventions, and targeted dietary strategies, are discussed in the context of their relevance for future clinical management of VC.